Status:
COMPLETED
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
Lead Sponsor:
Abbott
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
Eligibility Criteria
Inclusion
- Subject completed study M02-518 or M02-570
Exclusion
- Subject prematurely discontinued study M02-518 or M02-570
- Female subject who is pregnant or breast-feeding or considering becoming pregnant
- Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00195689
Start Date
August 1 2003
Last Update
August 29 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Global Medical Information-Abbott Laboratories
Abbott Park, Illinois, United States, 60064